Vikas Sukhatme, MD, ScD
-
Research Program
-
Email Address
Biography
Vikas Sukhatme MD, ScD, is the Robert W. Woodruff Professor of Medicine and former dean of Emory University School of Medicine. Dr. Sukhatme leads the Morningside Center for Innovative and Affordable Medicine, which promotes research, education and advocacy for affordable medical treatments with a focus on repurposed drugs. He is a member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute of Emory University.
Education
Dr. Sukhatme completed a bachelor's degree and then a doctorate (ScD) in theoretical physics at Massachusetts Institute of Technology. In 1979, he received an MD from Harvard Medical School in the Harvard-MIT program in Health Sciences and Technology. Following his residency in medicine and a clinical fellowship in nephrology at Massachusetts General Hospital, he spent two years at Stanford in immunology research.
Titles & Roles
-
Robert W. Woodruff Professor, Department of MedicineEmory University School of Medicine
-
Director and Co-founderMorningside Center for Innovative and Affordable Medicine
Research
Dr. Sukhatme's longstanding interest in cancer currently centers around tumor metabolism and tumor immunology and on "outside-of-the-box" approaches for treating advanced cancer. His research spans numerous areas of medicine in both fundamental science and clinical care, and he has conducted studies on genes important in kidney cancer and polycystic kidney disease.
| Title/Journal | Authors | Publication Date |
|---|---|---|
|
Why Certain Repurposed Drugs Are Unlikely to Be Effective Antivirals to Treat SARS-CoV-2 Infections. Viruses |
SJ Hurwitz, R De, JC LeCher, JA Downs-Bowen, SL Goh, K Zandi, T McBrayer, F Amblard, D Patel, JJ Kohler, M Bhasin, BS Dobosh, V Sukhatme, RM Tirouvanziam, RF Schinazi | 22/04/2024 |
|
Addendum: Resolvins suppress tumor growth and enhance cancer therapy. The Journal of experimental medicine |
ML Sulciner, CN Serhan, MM Gilligan, DK Mudge, J Chang, A Gartung, KA Lehner, DR Bielenberg, B Schmidt, J Dalli, ER Greene, Y Gus-Brautbar, J Piwowarski, T Mammoto, D Zurakowski, M Perretti, VP Sukhatme, A Kaipainen, MW Kieran, S Huang, D Panigrahy | 04/03/2024 |
|
Engaging Cancer Care Physicians in Off-Label Drug Clinical Trials: Human-Centered Design Approach. JMIR formative research |
MC Parsell, MN Greenleaf, GG Kombara, VP Sukhatme, WA Lam | 15/02/2024 |
|
Taxane chemotherapy induces stromal injury that leads to breast cancer dormancy escape. PLoS biology |
R Ganesan, SS Bhasin, M Bakhtiary, U Krishnan, NR Cheemarla, BE Thomas, MK Bhasin, VP Sukhatme | 01/09/2023 |
|
Clinical lung cancer |
NT Sebastian, WA Stokes, M Behera, R Jiang, DA Gutman, Z Huang, A Burns, V Sukhatme, MC Lowe, SS Ramalingam, VP Sukhatme, D Moghanaki | 01/05/2023 |
|
Impact of concomitant fibrates on immunotherapy outcomes for advanced non-small cell lung cancer. Cancer medicine |
WA Stokes, M Behera, R Jiang, DA Gutman, Z Huang, A Burns, NT Sebastian, V Sukhatme, MC Lowe, SS Ramalingam, VP Sukhatme, D Moghanaki | 01/01/2023 |
|
Frontiers in immunology |
M Coleman, SJ Mascialino, A Panjwani, E Edwards, VV Sukhatme, C Gavegnano, VP Sukhatme | 01/01/2023 |
|
Baricitinib attenuates the proinflammatory phase of COVID-19 driven by lung-infiltrating monocytes. Cell reports |
B Dobosh, K Zandi, DM Giraldo, SL Goh, K Musall, M Aldeco, J LeCher, VD Giacalone, J Yang, DJ Eddins, M Bhasin, E Ghosn, V Sukhatme, RF Schinazi, R Tirouvanziam | 14/06/2022 |
|
NMR in biomedicine |
G Varma, P Seth, P Coutinho de Souza, C Callahan, J Pinto, M Vaidya, O Sonzogni, V Sukhatme, GM Wulf, AK Grant | 01/08/2021 |
|
Available drugs and supplements for rapid deployment for treatment of COVID-19. Journal of molecular cell biology |
D Cicka, VP Sukhatme | 06/07/2021 |
|
Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19. Frontiers in pharmacology |
VP Sukhatme, AM Reiersen, SJ Vayttaden, VV Sukhatme | 01/01/2021 |
|
Cancer |
M Lowe, VV Sukhatme, VP Sukhatme | 01/09/2020 |
|
Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases. The Journal of clinical investigation |
D Panigrahy, A Gartung, J Yang, H Yang, MM Gilligan, ML Sulciner, SS Bhasin, DR Bielenberg, J Chang, BA Schmidt, J Piwowarski, A Fishbein, D Soler-Ferran, MA Sparks, SJ Staffa, V Sukhatme, BD Hammock, MW Kieran, S Huang, M Bhasin, CN Serhan, VP Sukhatme | 17/06/2019 |
|
Aspirin-triggered proresolving mediators stimulate resolution in cancer. Proceedings of the National Academy of Sciences of the United States of America |
MM Gilligan, A Gartung, ML Sulciner, PC Norris, VP Sukhatme, DR Bielenberg, S Huang, MW Kieran, CN Serhan, D Panigrahy | 26/03/2019 |
|
Proceedings of the National Academy of Sciences of the United States of America |
A Gartung, J Yang, VP Sukhatme, DR Bielenberg, D Fernandes, J Chang, BA Schmidt, SH Hwang, D Zurakowski, S Huang, MW Kieran, BD Hammock, D Panigrahy | 29/01/2019 |
|
Introduction: Repurposed Drugs: Teaching an Old Dog New Tricks. Cancer journal (Sudbury, Mass.) |
VP Sukhatme | 01/01/2019 |
|
Chemotherapy-generated cell debris stimulates colon carcinoma tumor growth via osteopontin. FASEB journal : official publication of the Federation of American Societies for Experimental Biology |
J Chang, SS Bhasin, DR Bielenberg, VP Sukhatme, M Bhasin, S Huang, MW Kieran, D Panigrahy | 01/01/2019 |